BP
AZN icon

Ballentine Partners’s AstraZeneca AZN Stock Holding History

Ballentine Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.81M Sell
20,071
-183
-0.9% -$34.4K 0.05% 133
2026
Q1 		$3.99M Buy
20,254
+1,942
+11% +$374K 0.06% 115
2025
Q4 		$3.37M Buy
18,312
+809
+5% +$142K 0.05% 130
2025
Q3 		$2.69M Buy
17,503
+372
+2% +$56.3K 0.04% 159
2025
Q2 		$2.39M Sell
17,131
-217
-1% -$30.4K 0.04% 170
2025
Q1 		$2.55M Buy
17,348
+2,087
+14% +$302K 0.04% 154
2024
Q4 		$2M Sell
15,261
-885
-5% -$124K 0.03% 174
2024
Q3 		$2.52M Buy
16,146
+1,782
+12% +$288K 0.04% 145
2024
Q2 		$2.24M Buy
14,364
+2,556
+22% +$385K 0.04% 146
2024
Q1 		$1.6M Buy
11,808
+2,898
+33% +$384K 0.03% 180
2023
Q4 		$1.2M Buy
8,910
+1,162
+15% +$151K 0.02% 205
2023
Q3 		$1.05M Sell
7,748
-150
-2% -$20.5K 0.02% 195
2023
Q2 		$1.13M Buy
7,898
+1,885
+31% +$277K 0.03% 184
2023
Q1 		$835K Sell
6,013
-20
-0.3% -$2.69K 0.02% 220
2022
Q4 		$818K Buy
6,033
+1,597
+36% +$200K 0.02% 196
2022
Q3 		$487K Sell
4,436
-233
-5% -$29.6K 0.02% 249
2022
Q2 		$618K Buy
4,669
+904
+24% +$119K 0.02% 209
2022
Q1 		$499K Buy
3,765
+11
+0.3% +$1.32K 0.02% 256
2021
Q4 		$437K Sell
3,754
-155
-4% -$18.2K 0.01% 297
2021
Q3 		$470K Buy
3,909
+322
+9% +$37.5K 0.02% 248
2021
Q2 		$430K Buy
3,587
+3
+0.1% +$329 0.01% 261
2021
Q1 		$356K Buy
3,584
+162
+5% +$16.3K 0.01% 274
2020
Q4 		$342K Sell
3,422
-245
-7% -$25.9K 0.01% 259
2020
Q3 		$402K Buy
3,667
+265
+8% +$29.5K 0.02% 231
2020
Q2 		$360K Buy
3,402
+117
+4% +$12.1K 0.02% 238
2020
Q1 		$293K Buy
3,285
+32
+1% +$3.01K 0.02% 249
2019
Q4 		$324K Buy
3,253
+408
+14% +$38.4K 0.01% 289
2019
Q3 		$254K Buy
2,845
+83
+3% +$7.2K 0.01% 318
2019
Q2 		$228K Buy
+2,762
New +$217K 0.01% 341

Other funds holding AZN

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
ZIC
ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return
CAM
Cidel Asset Management Toronto, Ontario, Ontario, Canada $2.08B AUM 24.89% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
PAS
Professional Advisory Services Vero Beach, Florida $836M AUM 25.79% 1-Year Est. Return
MIM
Martin Investment Management Palm Beach Gardens, Florida $300M AUM 6.05% 1-Year Est. Return
NONA
Ninety One North America New York $2.13B AUM 9.16% 1-Year Est. Return

Ballentine Partners's AZN Position: Q2 2026 in Review

Ballentine Partners reduced its AstraZeneca (AZN) stake by 0.9% in Q2 2026, selling an estimated $34.4K and leaving 20,071 shares worth $3.81M. The position accounts for 0.05% of the portfolio, ranked #133.

Ballentine Partners first reported a position in AZN in Q2 2019 and has held it in 29 quarters since. The position peaked at $3.99M in Q1 2026. 233 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Ballentine Partners held 20,071 shares of AstraZeneca worth $3.81M as of Q2 2026.
  • Ballentine Partners sold 183 AstraZeneca shares in Q2 2026, an estimated $34.4K.
  • AstraZeneca made up 0.05% of Ballentine Partners's portfolio in Q2 2026, its #133 holding.
  • Ballentine Partners first reported a position in AstraZeneca in Q2 2019 and has held it in 29 quarters since.
  • Ballentine Partners's AstraZeneca position peaked at $3.99M in Q1 2026.
  • 233 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.